3. Preetika Rana, Amy Dockser Marcus, and Wenxin Fan, “China, Unhampered by Rules, Races Ahead in Gene-Editing Trials,” Wall Street Journal, January 21, 2018, https://www.wsj.com/articles/china-unhampered-by-rules-races-ahead-in-gene-editing-trials-1516562360.
4. E. A. Stadtmauer et al., “CRISPR-engineered T cells in patients with refractory cancer,” Science 367, (2020): eaba7365, https://science.sciencemag.org/content/367/6481/eaba7365.
5. Carl June, Keystone Symposium, Banff, Canada, February 9, 2020.
6. G. E. Martyn et al., “Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding,” Nature Genetics 50, (2018): 498–503, https://www.nature.com/articles/s41588-018-0085-0.
7. M. H. Porteus, “A New Class of Medicines through DNA Editing,” New England Journal of Medicine 380, (2019): 947–959, https://www.nejm.org/doi/full/10.1056/NEJMra1800729.
8. Matthew Porteus, International Human Genome Editing Summit, Hong Kong, November 29, 2018.
9. David Sanchez in Human Nature (2019), https://wondercollaborative.org/human-nature-documentary-film/.
10. Rob Stein, “In a 1st, doctors In U.S. use CRISPR tool to treat patient with genetic disorder,” NPR, July 29, 2019, https://www.npr.org/sections/health-shots/2019/07/29/744826505/sickle-cell-patient-reveals-why-she-is-volunteering-for-landmark-gene-editing-st.
11. Rob Stein, “A Patient Hopes Gene-Editing Can Help With Pain Of Sickle Cell Disease,” NPR, October 10, 2019, https://www.npr.org/sections/health-shots/2019/10/10/766765780/after-a-life-of-painful-sickle-cell-disease-a-patient-hopes-gene-editing-can-hel.
12. Rob Stein, “A Young Mississippi Woman’s Journey Through a Pioneering Gene-Editing Experiment,” NPR, December 25, 2019, https://www.npr.org/sections/health-shots/2019/12/25/784395525/a-young-mississippi-womans-journey-through-a-pioneering-gene-editing-experiment.
13. Rob Stein, “A Year In, 1st Patient To Get Gene Editing For Sickle Cell Disease is Thriving,” NPR, June 23, 2020, https://www.npr.org/sections/health-shots/2020/06/23/877543610/a-year-in-1st-patient-to-get-gene-editing-for-sickle-cell-disease-is-thriving.
14. K. Davies and E. Charpentier, “Finding Her Niche: An Interview with Emmanuelle Charpentier,” CRISPR Journal 2, (2019): 17–22, https://doi.org/10.1089/crispr.2019.29042.kda.
15. Bill Gates, “Gene Editing for Good,” Foreign Affairs, May/June 2018, https://www.foreignaffairs.com/articles/2018-04-10/gene-editing-good.
16. Kevin Davies, “Avila Therapeutics Targets the Covalent Proteome,” Bio-IT World, January 28, 2010, http://www.bio-itworld.com/2010/01/28/avila.html.
17. M. L. Maeder et al., “Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10,” Nature Medicine 25, (2019): 229–233, https://www.nature.com/articles/s41591-018-0327-9.
18. Marilynn Marchione, “Doctors try 1st CRISPR editing in the body for blindness,” AP News, March 4, 2020, https://apnews.com/17fcd6ae57d39d06b72ca40fe7cee461.
19. Rob Wright, “A CEO’s most formative leadership experience,” Life Science Leader, February 25, 2019, https://www.lifescienceleader.com/doc/a-ceo-s-most-formative-leadership-experience-0001.
20. Rob Wright, “John Leonard’s latest adventure—readying Intellia Therapeutics for the long haul,” Life Science Leader, March 1, 2019, https://www.lifescienceleader.com/doc/john-leonard-s-latest-adventure-readying-intellia-therapeutics-for-the-long-haul-0001.
21. Alliance for Regenerative Medicine, “2017 Annual Dinner,” YouTube video, 1:10:07, last viewed May 2, 2020, https://www.youtube.com/watch?v=wPKyr092HlE.
22. Amy Dockser Marcus, “A year of brutal training for racing in the Andes,” Wall Street Journal, February 10, 2017, https://www.wsj.com/articles/a-year-of-brutal-training-for-racing-in-the-andes-1486814400.
23. Rodolphe Barrangou, interview, Victoria, Canada, February 21, 2019.
24. U. A. Neil, “A conversation with Eric Olson,” Journal of Clinical Investment 127, (2017): 403–404, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272177/.
25. L. Amoasii et al., “Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy,” Science 362, (2018): 86–91, https://science.sciencemag.org/content/362/6410/86.
26. V. Iyer et al., “No unexpected CRIPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice,” PLOS Genetics, July 9, 2018, https://doi.org/10.1371/journal.pgen.1007503.
27. J. H. Hu et al., “Chemical Biology Approaches to Genome Editing: Understanding, Controlling and Delivering Programmable Nucleases,” Cell Chemical Biology 23, (2016): 57–73, https://doi.org/10.1016/j.chembio.2015.12.009.
28. M. Kosicki et al., “Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements,” Nature Biotechnology 36, (2018): 765–771, https://www.nature.com/articles/nbt.4192.
29. C. T. Charlesworth et al., “Identification of preexisting adaptive immunity to Cas9 proteins in humans,” Nature Medicine 25, (2019): 249–254, https://www.nature.com/articles/s41591-018-0326-x.
30. A. Mehta and O. M. Merkel, “Immunogenicity of Cas9 Protein,” Journal of Pharmaceutical Sciences 109, (2020): 62–67, https://pubmed.ncbi.nlm.nih.gov/31589876/.
31. T. Ho and D. P. Lane, “Guardian of Genome Editing,” CRISPR Journal 1, (2018): 258–260, https://www.liebertpub.com/doi/10.1089/crispr.2018.29021.dal.